Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN65GW
|
|||
| Drug Name |
LY3475070
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ecto-5'-nucleotidase (CD73) | Target Info | Inhibitor | [2] |
| BioCyc | Purine nucleotides degradation | |||
| Urate biosynthesis/inosine 5'-phosphate degradation | ||||
| Adenosine nucleotides degradation | ||||
| KEGG Pathway | Purine metabolism | |||
| Pyrimidine metabolism | ||||
| Nicotinate and nicotinamide metabolism | ||||
| Metabolic pathways | ||||
| Panther Pathway | Purine metabolism | |||
| Pyrimidine Metabolism | ||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Purine catabolism | |||
| WikiPathways | Differentiation Pathway | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Metabolism of nucleotides | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04148937) A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 2 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.